1例彭氏变形杆菌致糖尿病足感染的药学监护

doi:10.19803/j.1672-8629.20240682

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (8): 937-940.
DOI: 10.19803/j.1672-8629.20240682

1例彭氏变形杆菌致糖尿病足感染的药学监护

赵牡丹¹, 朱明辉¹, 张欢¹, 赵远洋², 秦靖^1*

¹东南大学医学院附属南京同仁医院药学部,江苏南京 211102;
²东南大学医学院附属南京同仁医院内分泌科,江苏南京 211102

收稿日期:2024-08-29 出版日期:2025-08-15 发布日期:2025-08-13
通讯作者: ^*秦靖,女,本科,主管药师,临床药学。E-mail: 15951733801@163.com
作者简介:赵牡丹,女,本科,主管药师,临床药学。

Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri

ZHAO Mudan¹, ZHU Minghui¹, ZHANG Huan¹, ZHAO Yuanyang², QIN Jing^1*

¹Department of Pharmacy, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing Jiangsu 211102, China;
²Department of Endocrine, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing Jiangsu 211102, China

Received:2024-08-29 Online:2025-08-15 Published:2025-08-13

摘要/Abstract

摘要： 目的探讨临床药师在糖尿病足感染患者的抗感染方案制定、诊治过程中方案的调整以及药学监护的作用。方法临床药师参与1例彭氏变形杆菌致糖尿病足感染合并糖尿病肾病的患者抗感染治疗,药师通过询问病史及结合临床指南,发现彭氏变形杆菌对替加环素天然耐药,后根据药敏试验调整为头孢哌酮钠舒巴坦钠抗感染,协助临床医师为患者提供个体化给药方案及药学监护。结果临床药师及时调整糖尿病足抗感染方案,患者感染指标逐渐恢复正常,感染部位逐渐长出新生肉芽组织,治疗效果有效,患者病情好转出院。结论临床药师通过参与1例彭氏变形杆菌导致糖尿病足感染合并糖尿病肾病的患者抗感染治疗并进行用药监护,有助于降低不良反应,优化药物治疗效果,提升临床合理用药水平。

关键词: 糖尿病足感染, 彭氏变形杆菌, 糖尿病肾病, 药品不良反应, 药学监护, 临床药师

Abstract: Objective To explore the role of clinical pharmacists in the formulation of an anti infective program for diabetic foot infection and in the adjustment of the program in the process of diagnosis and treatment, and the importance of pharmaceutical care. Methods Four clinical pharmacists participated in the anti infection treatment of a patient with diabetic foot infection and diabetic nephropathy caused by Proteus penneri. The pharmacists found that Proteus penneri was naturally resistant to tegacycline by inquiring about the patient’s medical history and consulting clinical guidelines before they shifted to cefoperazone sodium and sulbactam sodium according to the drug sensitivity. The pharmacists also assisted the clinicians in providing individualized drug delivery programs and pharmaceutical care for patients. Results The clinical pharmacists adjusted the anti infection scheme of the diabetic foot quickly, the infection index of the patient returned to normal, new granulation tissue was gradually formed at the infection site, the therapeutic effect was pronounced, and the patient was discharged. Conclusion The participation of clinical pharmacists in anti infection treatment of and pharmaceutical care for a patient with diabetic foot infection and diabetic nephropathy caused by Proteus penneri can help to reduce adverse reactions, optimize the effects of medications, and rationalize clinical drug use.

Key words: Diabetic Foot Infection, Proteus penneri, Diabetic Nephropathy, Adverse Drug Reaction, Pharmaceutical Care, Clinical Pharmacist

中图分类号:

赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.

ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240682

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I8/937

参考文献

[1] The National Bureau of Disease Control and Prevention. Report on Chinese Residents' Chronic Diseases and Nutrition(中国居民营养与慢性病状况报告)(2020)[M]. Beijing: People's Medical Publishing House, 2021.
[2] VAN-NETTEN JJ, BUS SA, APELQVIST J, et al.Definitions and Criteria for Diabetic Foot Disease[J]. Diabetes-Metabolism Research and Reviews, 2020, 36( Suppl 1): e3268.
[3] ZHANG P, LU J, JING Y, et al.Global Epidemiology of Diabetic Foot Ulceration: a Systematic Review and Meta-Analysis[J]. Annals of Medicine, 2017, 49(2): 106-116.
[4] ARMSTRONG DG, TAN TW, BOULTON AJM, et al.Diabetic Foot Ulcers: a Review[J]. The Journal of the American Medical Association, 2023, 330(1): 62-75.
[5] WEI N, ZHANG P, GUO XS, et al.Literature Analysis on the Adverse Reactions of Linezolid and Points of Pharmaceutical Care[J].China Pharmaceuticals(中国药业), 2016, 25(8): 90-93.
[6] KISHORE J.Isolation, Identification & Characterization of Proteus Penneri-a Missed Rare Pathogen[J]. Indian Journal of Medical Research, 2012, 135(3): 341-345.
[7] XU YM, DONG XX, SHAN B, et al.Changing Resistance Profiles of Proteus, Morganella and Providencia in Hospitals Across China: Results from the China Antimicrobial Resistance Surveillance Program, 2015-2021[J]. Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志), 2024, 24(4): 410-417.
[8] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, M100(M100抗微生物药物敏感性试验执行标准第31版)[M]. 31st ed. Beijing: China Antimi-crobial Surveillance Network, 2021.
[9] WANG Z, WU Y, CHEN S, et al.Infection of Diabetes Foot Caused by Carbapenem-Resistant Proteus Penneri Mediated by a Novel Plasmid Containing blaNDM[J]. Infect Drug Resist, 2023, 16: 1099-1106.
[10] MUNIM MA, DAS SC, HOSSAIN MM, et al.Multi-Drug Resistant (MDR) Gram-Negative Pathogenic Bacteria Isolated from Poultry in the Noakhali Region of Bangladesh[J]. Public Library of Science One, 2024, 19(8): e0292638.
[11] LAUPLAND KB, EDWARDS F, HARRIS PNA.Proteus Species Bloodstream Infections: Comparative Epidemiology of Three Species[J]. Diagnostic Microbiology and Infectious Disease, 2024, 109(2): 116286.
[12] Guidelines for Clinical Use of Antibiotics Revision Working Group. Guidelines for Clinical Use of Antibiotics: (抗菌药物临床应用指导原则)[M]. Beijing:People's Medical Publishing House, 2015.
[13] Chinese Diabetes Society.Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China(2020 Edition)[J]. Chinese Journal of Diabetes Mellitus(中华糖尿病杂志), 2021, 13(4): 315-409.
[14] Branch Group of Diabetic Foot and Peripheral Vascular Disease, Chinese Diabetes Society. Clinical Pathway for the Management of Diabetic Foot in China(2023 Edition)[J]. Chinese Journal of Endocri-nology and Metabolism(中华内分泌代谢杂志), 2023, 39(2): 93-102.
[15] DU F, MA J, GONG H, et al.Microbial Infection and Antibiotic Susceptibility of Diabetic Foot Ulcer in China: Literature Review[J]. Frontiers in Endocrinology, 2022, 13: 881659.
[16] CHEN T, YU J, YE J, et al.Infection Characteristics and Drug Susceptibility of Multidrug-Resistant Bacteria in Patients with Diabetic Foot Ulcers[J]. Clinical Laboratory, 2023, 69(9): 230309.
[17] MACDONALD KE, BOECKH S, STACEY HJ, et al.The Microbiology of Diabetic Foot Infections: a Meta-Analysis[J]. BMC Infectious Diseases, 2021, 21(1): 770.
[18] SULUDERE MA, ÖZ OK, ROGERS LC, et al.MRSA Infection, Re-Infection and Clinical Outcomes in Diabetic Foot Infections[J]. Wound Repair Regen, 2024, 32(4): 377-383.
[19] ZHANG JQ.Analysis of the Clinical Characteristics and Pop PK Study of Linezolid in Diabetic Foot Patients[D]. Yantai : Yantai University, 2023.
[20] JU G, ZHANG Y, YE C, et al.Comparative Effectiveness and Safety of Six Antibiotics in Treating MRSA Infections: a Network Meta-Analysis[J]. The International Journal of Infectious Diseases, 2024, 146: 107109.
[21] HEIDARI S, KHALILI H.Linezolid Pharmacokinetics: a Syste-matic Review for the Best Clinical Practice[J]. The European Journal of Clinical Pharmacology, 2023, 79(2): 195-206.

1例彭氏变形杆菌致糖尿病足感染的药学监护

Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李明颖, 张晓霞, 孙晓黎, 赵燕, 何苗, 李艳玲, 段薇, 杨鸥. 舒更葡糖钠对腹腔镜全盆底重建术后患者恢复的影响[J]. 中国药物警戒, 2025, 22(8): 896-901.
[2]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[3]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[4]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[5]	陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.
[6]	杨欣, 杨宝春, 杨漾, 邵欢. 信迪利单抗致内分泌系统不良反应1例分析[J]. 中国药物警戒, 2025, 22(8): 947-949.
[7]	王春婷, 陈亚飞, 李婷婷. 化学药品上市后说明书安全信息修订考虑要点[J]. 中国药物警戒, 2025, 22(7): 776-779.
[8]	朱会卷, 任经天. 狂犬病人免疫球蛋白安全性风险分析[J]. 中国药物警戒, 2025, 22(7): 786-789.
[9]	陈耀哲, 詹云丽, 宋兴栋, 朱漫玉, 欧雪媚, 李楚云. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798.
[10]	曹凯, 钱佩佩, 高鑫, 杨付田, 赵亮, 徐炳欣, 张现军. 基于美国FAERS数据库的药物引起唾液腺结石不良事件信号分析[J]. 中国药物警戒, 2025, 22(7): 799-804.
[11]	林璐, 赵安职, 陈锦辉, 李忠文, 黄国华, 钟诗龙. 注射用头孢噻肟钠舒巴坦钠致迟发型超敏反应1例分析[J]. 中国药物警戒, 2025, 22(7): 809-811.
[12]	唐炯, 曾语琦. 舒格利单抗注射液致动眼神经麻痹1例分析[J]. 中国药物警戒, 2025, 22(7): 812-814.
[13]	王媛, 李若柠, 郭展立, 张磊, 李嘉媛, 冬颖, 孙建军. 替罗非班注射液致极重度血小板减少症1例分析[J]. 中国药物警戒, 2025, 22(7): 815-818.
[14]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.
[15]	李敏, 李春磊, 孙翠翠, 于文雯, 孙青, 戚迎梅, 刘安昌. 阿布昔替尼片致急性泛发性发疹性脓疱病1例分析[J]. 中国药物警戒, 2025, 22(7): 823-825.